Garrett Winslow - 23 Mar 2026 Form 4 Insider Report for Damora Therapeutics, Inc. (DMRA)

Reporting relationship: General Counsel
Issuer ticker: DMRA
Reported as of: 23 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Mar 2026, 18:09:57 UTC
Prior SEC filing: 06 Jan 2026
Next SEC filing: 07 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Garrett Winslow

Key filing fact

Garrett Winslow filed Form 4 for Damora Therapeutics, Inc. (DMRA) on 25 Mar 2026.

Key facts

This page summarizes Garrett Winslow's Form 4 filing for Damora Therapeutics, Inc. (DMRA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 25 Mar 2026, 18:09.

Change

Previous filing in this sequence was filed on 06 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001803773 Primary reporting owner

Winslow Garrett

Relationship: General Counsel
Address: C/O DAMORA THERAPEUTICS, INC.,, 221 CRESCENT ST, BUILDING 23, SUITE 105, WALTHAM
Signature: /s/ Garrett Winslow
Signature date: 25 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DMRA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +250,000
Change %
Price: $0.000000^*
Shares after: 250,000
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250,000
Exercise price: $23.05
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents a right to purchase shares of common stock of the Issuer. This option will vest as to 25% on March 23, 2027 and in equal monthly installments thereafter through March 23, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.